Since PARP10 is overexpressed in a significant proportion of breast and ovarian cancer tumors, we reasoned that our screening setup may mimic the situation in cancer patients, with PARP10 being overexpressed in the tumor cells but not in the normal tissue. This evidence concerns the gene PARP10 and ovarian cancer.